Nadav Liam Modlin
Psychology and Psychotherapy Lead in Psychedelics at King’s College London
Data updated
Research Footprint
Nadav Liam Modlin appears in 7 tracked papers (2021–2025), most studied alongside Psilocybin and MDMA, across Depressive Disorders, PTSD and Treatment-Resistant Depression (TRD).
Most-cited paper: Psilocybin and MDMA for the treatment of trauma-related psychopathology (76 citations).
Frequent co-authors: James Rucker, Namik Kirlic and Guy Goodwin.
Background & Research
Nadav Liam Modlin is a psychotherapist and psychedelic researcher based at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience. His work centers on the psychotherapy and participant-support aspects of psychedelic clinical trials, especially psilocybin studies in PTSD and treatment-resistant depression. He has coauthored qualitative, protocol, and model papers on psychedelic therapy delivery, including COMP360 support methods and trauma-informed care.
Key Impact
He is a leading psychotherapy researcher on psilocybin studies for PTSD and treatment-resistant depression, with a strong focus on participant experience, preparation, and trauma-informed support models.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Nadav Liam Modlin is associated with.
King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →